CJC-1295 With DAC vs No DAC: Researcher's Guide to Structural Differences, Release Kinetics & Preclinical Study Comparisons (2026)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has attracted sustained interest in peptide research circles due to its structural modifications over the native peptide sequence. Two primary variants exist in the research landscape: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also referred to as Mod GRF 1-29). While both share a common GHRH-derived backbone, the presence or absence of the DAC technology fundamentally alters their pharmacokinetic profiles, binding behavior, and the types of research questions they are best suited to explore.

Understanding the molecular distinctions between these two variants is essential for researchers designing preclinical study protocols that investigate pulsatile versus sustained growth hormone (GH) secretion patterns, pituitary signaling dynamics, and downstream IGF-1 axis modulation. This guide provides a structured comparison of both forms, drawing on published preclinical findings and receptor biology to help laboratory scientists contextualize their research approach.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

IGF — 1 LR3 1MG

IGF-1 LR3 1MG — Research-Grade Reference Material IGF-1 LR3 1MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$65.00 ($48.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is the main structural difference between CJC-1295 with DAC and CJC-1295 without DAC?

CJC-1295 with DAC incorporates a lysine-maleimide linker conjugated to a fatty acid chain (the Drug Affinity Complex), which enables covalent binding to serum albumin in vivo. CJC-1295 without DAC (Mod GRF 1-29) retains the core 29-amino-acid GHRH analog sequence but lacks this albumin-binding modification, resulting in a dramatically shorter half-life in preclinical models.

What does DAC stand for in CJC-1295 with DAC?

DAC stands for Drug Affinity Complex. It refers to a reactive maleimide group attached to the peptide via a lysine residue that can form a covalent thioether bond with a cysteine-34 residue on circulating serum albumin, effectively using albumin as a carrier to extend the peptide’s circulatory half-life in preclinical models.

How do the half-lives of CJC-1295 with DAC and without DAC compare in preclinical studies?

Preclinical and early research models have indicated that CJC-1295 without DAC has a half-life estimated in minutes (approximately 30 minutes), consistent with endogenous GHRH analogs. CJC-1295 with DAC has demonstrated a substantially extended half-life in the range of several days in animal models, owing to its albumin-binding mechanism.

What is Mod GRF 1-29 and how does it relate to CJC-1295 No DAC?

Mod GRF 1-29 is an alternative designation for CJC-1295 without DAC, used in research literature to denote the 29-amino-acid modified GHRH fragment. Both names refer to the same compound: a GHRH analog with four key amino acid substitutions relative to native GHRH(1-29) that improve enzymatic stability while preserving receptor affinity.

Why do researchers combine CJC-1295 No DAC with Ipamorelin in preclinical studies?

Studies have investigated the pairing of CJC-1295 No DAC with Ipamorelin because the two peptides act on complementary receptor pathways — GHRH receptor and ghrelin/GHS-R1a receptor, respectively. Research suggests this combination may produce additive or synergistic effects on pulsatile GH release in animal models, mimicking physiological GH secretion patterns more closely than either compound alone.

Is CJC-1295 with DAC suitable for studying sustained GH axis modulation in preclinical models?

Research suggests that CJC-1295 with DAC is useful for investigating prolonged, tonic stimulation of the GHRH receptor pathway in preclinical models due to its extended albumin-bound half-life. This makes it a relevant tool for studying sustained IGF-1 axis responses, as observed in rodent studies examining multi-day GH release profiles.

What are the four amino acid substitutions in CJC-1295 No DAC compared to native GHRH(1-29)?

The four substitutions in Mod GRF 1-29 (CJC-1295 No DAC) are: Ala2 → D-Ala2, Gln8 → Ala8, Ala15 → His15 (or similar variant), and Leu27 → Met27 (depending on the specific synthesis). These modifications collectively reduce dipeptidyl peptidase IV (DPP-IV) cleavage and oxidative degradation, improving the compound’s stability in biological matrices for research purposes.

Can CJC-1295 with DAC and without DAC be studied together in the same preclinical protocol?

Some preclinical research protocols have examined both variants within comparative frameworks to contrast pulsatile versus sustained GH secretion paradigms. Researchers studying GH axis biology may design studies using each form separately or sequentially to understand how release kinetics influence downstream signaling outcomes in animal models.

Structural Biology: What Separates These Two Variants at the Molecular Level

Both CJC-1295 variants originate from the same foundational scaffold: a modified 29-amino-acid fragment of endogenous GHRH. Native GHRH(1-44) is the hypothalamic peptide responsible for stimulating anterior pituitary somatotrophs to release growth hormone. GHRH(1-29) retains full receptor agonist activity at the GHRH receptor, and Mod GRF 1-29 (CJC-1295 No DAC) represents a further stabilized version of this fragment with strategic amino acid substitutions to resist proteolytic degradation.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

IGF — 1 LR3 1MG

$65.00 ($48.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

The introduction of the DAC modification transforms CJC-1295 No DAC into a structurally distinct molecule. A reactive maleimide-containing linker is attached to a lysine residue (typically at position 17 or via an appended lysine), conjugated to a long-chain fatty acid. This construct is designed to react with the free thiol group of cysteine-34 on serum albumin, forming a stable thioether bond. The result is an albumin-bound peptide that circulates for an extended duration, slowly releasing its bioactive GHRH-agonist component over days in animal models. This albumin-binding strategy is analogous to approaches explored in other long-acting peptide research programs.

Key Structural Summary

Feature	CJC-1295 with DAC	CJC-1295 No DAC (Mod GRF 1-29)
Core sequence	Modified GHRH(1-29) analog	Modified GHRH(1-29) analog
DAC modification	Present (maleimide-lysine-fatty acid)	Absent
Albumin binding	Covalent thioether bond to Cys-34	None
Approximate half-life (preclinical)	~5–8 days (animal models)	~20–30 minutes
GH release pattern (preclinical)	Sustained / tonic elevation	Pulsatile / physiological
Molecular weight	~3,647 Da (with DAC linker)	~3,357 Da
Primary research application	Sustained GH/IGF-1 axis studies	Pulsatile GH secretion studies

Release Kinetics: Pulsatile vs Sustained Paradigms in Preclinical Research

One of the most significant distinctions between the two variants lies in the GH release kinetics they produce in preclinical models, and this has meaningful implications for how researchers design and interpret studies.

CJC-1295 No DAC: Pulsatile Release Kinetics

Without the DAC modification, CJC-1295 No DAC behaves much like an enhanced version of endogenous GHRH — it occupies GHRH receptors on pituitary somatotrophs, triggers GH secretion, and is then cleared rapidly from the system. In rodent models, this produces a sharp, pulse-like elevation in circulating GH that mirrors the physiological patterns observed with endogenous GHRH signaling.

This pulsatile kinetic profile makes CJC-1295 No DAC particularly valuable for research paradigms investigating the timing-sensitivity of GH axis signaling, somatotroph responsiveness, or studies where mimicking natural GH secretion architecture is scientifically important. As explored in the CJC-1295 No DAC + Ipamorelin stack research guide, combining this GHRH analog with a ghrelin receptor agonist has been a popular preclinical strategy for investigating amplified pulsatile GH outputs through dual-receptor engagement.

CJC-1295 with DAC: Sustained Tonic Stimulation

The DAC-modified variant presents a fundamentally different research utility. By binding to serum albumin shortly after introduction into a biological system, CJC-1295 with DAC creates a long-duration reservoir of GHRH-receptor agonist activity. Preclinical studies in rodent models have demonstrated that this can maintain elevated IGF-1 and GH levels for multiple days following a single exposure, providing researchers with a tool for studying chronic GHRH receptor activation without repeated interventions.

A pivotal early study by Jetté et al. (2005) examining CJC-1295 with DAC in animal models reported extended GH and IGF-1 elevations consistent with the albumin-binding half-life hypothesis. This sustained kinetic pattern opens distinct research questions about prolonged somatotropic stimulation, hypothalamic feedback regulation, and long-duration IGF-1 axis changes — research questions that the short-acting No DAC variant is ill-suited to address.

The broader mechanistic context of GHRH receptor biology and CJC-1295’s molecular pharmacology is detailed in the CJC-1295 Peptide Research Guide, which covers receptor coupling, second messenger cascades, and the structural rationale for each amino acid modification in the Mod GRF 1-29 backbone.

Preclinical Study Comparisons: What the Research Literature Reveals

Animal Model Findings: CJC-1295 with DAC

The foundational preclinical work on CJC-1295 with DAC was conducted primarily in rodent and canine models. A study published by Jetté et al. in the Journal of Clinical Endocrinology & Metabolism (2005) examined CJC-1295 with DAC in rats and monkeys, reporting dose-dependent increases in plasma GH and IGF-1 levels that persisted for several days. The study’s findings were consistent with the expected albumin-binding pharmacokinetics and suggested robust GHRH receptor engagement over extended timeframes.

Importantly, the sustained elevation in IGF-1 observed in these models raised research questions about potential desensitization of somatotroph cells under prolonged GHRH receptor stimulation — a topic that continues to be explored in GH axis biology research. Whether tonic versus pulsatile stimulation differentially affects GHRH receptor downregulation is a nuanced question that comparative studies of both CJC variants can help illuminate.

Animal Model Findings: CJC-1295 No DAC

Preclinical research examining CJC-1295 No DAC in isolation has focused primarily on its ability to amplify pulsatile GH secretion in rodent models. Studies have investigated GHRH receptor occupancy kinetics, the magnitude of GH pulses relative to native GHRH(1-44), and the compound’s resistance to DPP-IV cleavage compared to unmodified GHRH fragments.

The pairing of CJC-1295 No DAC with ghrelin receptor agonists like Ipamorelin has been extensively studied. As reviewed in the Ipamorelin mechanisms and research applications guide, Ipamorelin acts on the GHS-R1a receptor through a distinct signaling pathway to that of GHRH, and preclinical studies have investigated whether these two pathways produce additive GH release when engaged simultaneously in animal models.

Comparative Observations Across Studies

When preclinical findings from both variants are placed side by side, several patterns emerge in the literature:

IGF-1 elevation duration: CJC-1295 with DAC studies consistently report multi-day IGF-1 elevations in animal models; No DAC studies report transient elevations aligned with the compound’s short half-life.
GH pulse architecture: No DAC studies preserve discrete GH pulse patterns; DAC studies show a blunted, sustained GH elevation that disrupts normal pulsatile architecture.
Receptor sensitivity: Some preclinical literature has raised the hypothesis that prolonged GHRH receptor stimulation (as modeled with the DAC variant) may influence receptor desensitization dynamics differently than pulsatile stimulation — though this remains an active area of investigation.
Downstream signaling: Both variants engage the adenylyl cyclase / cAMP / PKA pathway through GHRH receptor coupling, with differences in downstream signaling duration reflecting their respective kinetic profiles.

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

Choosing the Right Variant for Your Research Protocol

Choose CJC-1295 with DAC if…

The research question involves studying sustained, multi-day GH or IGF-1 axis modulation in animal models
The protocol benefits from less frequent compound administration in preclinical settings
The study design investigates prolonged GHRH receptor engagement and potential somatotroph desensitization
The focus is on albumin-binding pharmacokinetics as a delivery mechanism model

Choose CJC-1295 No DAC if…

The research question specifically involves pulsatile GH secretion dynamics and physiological mimicry
The protocol requires precise temporal control over GH release timing in in vitro or in vivo models
The study involves combination with ghrelin receptor agonists (such as Ipamorelin) to model dual-receptor GH axis activation
Investigating DPP-IV resistance of modified GHRH analogs is a key endpoint

CJC1295 with DAC – 5MG Nasal Spray for research →

CJC 1295 No DAC + Ipamorelin – 10MG Nasal Spray for research →

CJC 1295 No DAC + Ipamorelin – 20MG for research →

Related Research Contexts: GH Axis Biology Intersections

Researchers studying CJC-1295 variants often situate their work within broader GH axis and metabolic research frameworks. The mitochondrial and metabolic angles of growth-related peptide research are increasingly explored alongside GH secretagogue biology — for instance, the MOTS-C peptide research guide explores mitochondrial regulation of metabolic signaling pathways that intersect with anabolic and growth-related biology in preclinical models.

Similarly, researchers interested in the downstream tissue-level effects of GH axis activation may find relevant mechanistic parallels in BPC-157 and TB-500 stack research, which investigates tissue remodeling and repair pathways that can be influenced by the broader anabolic signaling environment modulated by GHRH analogs in preclinical models.

Ipamorelin – 10MG Nasal Spray for research →

Where These Fit in Your Research Library

Both CJC-1295 variants occupy distinct and complementary positions in GHRH biology research. Researchers building a comprehensive GH axis research library may wish to reference:

CJC1295 with DAC – 5MG Nasal Spray for sustained GHRH receptor agonism studies
CJC 1295 No DAC + Ipamorelin – 10MG Nasal Spray for pulsatile GH secretion and dual-receptor research
The full SourcePeptides research catalog for additional GH axis, metabolic, and neuropeptide research compounds

Final Takeaway

CJC-1295 with DAC and CJC-1295 without DAC represent two structurally related but functionally distinct tools for investigating GHRH receptor biology and GH axis physiology in preclinical models. The DAC modification fundamentally extends the compound’s half-life through albumin binding, enabling studies of sustained tonic GH and IGF-1 elevation, while the No DAC variant preserves the pulsatile kinetic architecture that more closely mirrors endogenous GHRH signaling. Researchers selecting between these two variants should be guided by their specific study endpoints — whether the question concerns duration of GH axis stimulation, pulsatile release dynamics, combination receptor strategies, or fundamental pharmacokinetic modeling. Both variants continue to appear in the preclinical literature as valuable reference tools for understanding one of the most important axes in endocrine biology.

Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

📚 Complete Bpc 157 Series

CJC-1295 With DAC vs No DAC: Researcher’s Guide to Structural Differences, Release Kinetics & Preclinical Study Comparisons (2026)